ESE Focus Area Update: Adrenal and Neuroendocrine Tumours
ESE Focus Area Update:
Adrenal and Neuroendocrine Tumours
Adrenal and Neuroendocrine Tumours: the latest advances
Welcome to the first ESE Focus Area Update for Adrenal and Neuroendocrine tumours. The Focus Area Updates provide the endocrine community with news, upcoming activities and developments in their areas of interest. The Adrenal and NET Focus Area Update has been developed by the ESE Focus Area for Adrenal and Neuroendocrine Tumours.
This edition focuses on the latest advances in adrenal and neuroendocrine tumours, looking at the use of circulating blood-borne microRNAs as the minimally invasive markers in adrenal tumors and tumor growth rate as a validated early radiological biomarker able to reflect treatment-induced changes in neuroendocrine tumor. Also, it focuses on biochemical markers in heterozygous carriers of CYP21 mutations. Further, we cover the latest ENS@T news and the 7th International Adrenocortical Carcinoma Symposium held in Clermont-Ferrand (France).
Guest Editor: Ljiljana Marina
Contributors: Ashley Grossman, Darko Kastelan, Tatjana Isailovic, Attila Patócs, Guillaume Assie
New fast and accurate technique for assessing tumour response to treatment
It is often difficult to assess whether neuroendocrine tumours (NETs) have responded to therapy using the assessment of RECIST criteria. Dr Angela Lamarca introduces a new measurement called 'tumour growth rate' which can sensitively demonstrate responses to treatment over short time periods. This rapid technique could be valuable in clinical practice and clinical trials.
The potential of MicroRNAs as markers in adrenal tumours
Professor Peter Igaz, from Semmelweis University in Budapest, Hungary, discusses the role of circulating blood-borne microRNAs as minimally invasive markers in adrenal tumours.
New tool to determine heterozygous carriers of CYP21 mutations
The diagnosis of heterozygous carriers of CYP21 mutations is challenging for clinicians, due to clinical overlapping with other forms of CAH and conditions such as polycystic ovary syndrome. Valentina Guarnotta and Carla Giordano discuss the role of 17OHP/cortisol ratio as an effective, simple tool to determine heterozygous carriers of CYP21 mutations.
How ENS@T is improving our understanding of adrenal tumours
Professor Darko Kastelan provides insight into the work carried out by the European Network for the Study of Adrenal Tumours (ENS@T), one of the largest networks for scientists and clinicians. (ENS@T) aims to facilitate collaboration between experts to improve understanding and management of adrenal tumours. The annual meeting will take place in Zurich on 5-6 November 2020.
International Adrenocortical Carcinoma Symposium update
Read the highlights from the 7th International Adrenocortical Carcinoma Symposium held in Clermont-Ferrand, France, September 2019. The symposium provided a strong basic science update, including mouse and cell-line models for better understanding of tumorigenesis and testing drugs. Read the complete list of abstracts.
PAPERS OF INTEREST
Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Cejas P et al., Nat Med. (Aug 2019) Full article
Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia. Bosch F, et al., Endocr Relat Cancer. (Mar 2019) Full article
T2D in Neuroendocrine Tumors: Are Biguanides, Statins Part of the Solution?. Herrera Martínez AS, et al., J Clin Endocrinol Metab (Jan 2019)Full article
Transcriptome analysis of lncRNAs in pheochromocytomas and paragangliomas. Job S, et al., J Clin Endocrinol Metab (Nov 2019) Full article
The Adipose Stem Cell as a Novel Metabolic Actor in Adrenocortical Carcinoma Progression: Evidence from an In Vitro Tumor Microenvironment Crosstalk Model. Armignacco R, et al., Cancers (Basel). (Dec 2019) Full article
Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: Particular importance for early infancy. Peitzsch M, et al., Epub (Mar 2020) Full article
Urine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma. Chortis V, et al., J Clin Endocrinol Metab (Oct 2019) Full article
Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis. Elhassan YS, et al., Epub. (Jun 2019) Full article
10 - 11 March 2020, First World NET forum, Barcelona, Spain
11 - 13 March 2020, 17th annual ENETS conference, Barcelona, Spain
11 March 2020, Annual ENETS Postgraduate Course, Barcelona, Spain
27 - 29 April 2020, NET Academy 2020, London, UK
1 - 3 Oct 2020, NANETS Multidisciplinary NET Medical Symposium, Montréal, Québec
5 - 6 Nov 2020, 19th ENSAT Scientific Meeting, Zurich, Switzerland
European Society of Endocrinology
Starling House, 1600 Bristol Parkway North, Bristol BS34 8YU
You are receiving this email because you signed up to our mailing list or at some point have worked with us. This email and any files transmitted with it are intended solely for the use of the individual or entity to whom they are addressed, and may contain confidential information. If you have received this e-mail in error please notify firstname.lastname@example.org. If you no longer wish to receive these emails, you can unsubscribe instantly.